For the Quarter Ending March 2026
Potassium Clavulanate Prices in APAC
- In China, the Potassium Clavulanate Price Index rose by 4.54% quarter-over-quarter, reflecting a modest cost push.
- The average Potassium Clavulanate price for the quarter was approximately USD 63,970/MT, reflecting export-led restocking demand.
- Domestic output tightness reduced spot availability, pushing Potassium Clavulanate Spot Price higher in export hubs.
- Rising feedstock costs drove the Potassium Clavulanate Production Cost Trend upward, squeezing manufacturers' crystallization margins.
- Forward bookings and export demand informed the Potassium Clavulanate Price Forecast, indicating cautious near-term firmness.
- Hospital procurement cycles and reformulation trends supported the Potassium Clavulanate Demand Outlook for sustained consumption.
- Inventory cover tightened to three weeks, maintaining Potassium Clavulanate Price Index strength during constrained supply.
- Producers prioritized confirmed export orders, reflecting disciplined inventory management and steady operational utilization near-term patterns
Why did the price of Potassium Clavulanate change in March 2026 in APAC?
- Feedstock Caustic Potash surged, raising conversion expenses and pushing sellers to pass through higher costs.
- Environmental audits curtailed fermentation runs, reducing spot availability and shortening inventory buffers at coastal warehouses.
- Robust domestic hospital procurement and redirected export enquiries from Europe elevated demand for Chinese supplies
Potassium Clavulanate Prices in Europe
- In Germany, the Potassium Clavulanate Price Index rose by 5.49% quarter-over-quarter, driven by FOB offers.
- The average Potassium Clavulanate price for the quarter was approximately USD 64668.33/MT, weighted monthly calculation
- Potassium Clavulanate Spot Price strengthened in March as allocations and caustic potash costs persisted abroad
- Exporters maintained disciplined CFR offers; Potassium Clavulanate Price Forecast suggests modest gains amid restocking dynamics.
- Caustic Potash elevated Potassium Clavulanate Production Cost Trend, raising neutralization and spray-drying expenses for manufacturers.
- Potassium Clavulanate Demand Outlook remains stable with hospital tender restocking supporting purchases through early spring.
- Inventory levels at distributors were comfortable, Potassium Clavulanate Price Index remained firm due to spot availability.
- Logistics pressures and higher ocean rates increased landed costs, supporting Potassium Clavulanate Price Index resilience.
Why did the price of Potassium Clavulanate change in March 2026 in Europe?
- Stronger Asian FOB offers and higher Caustic Potash feedstock prices pushed landed import parity upward.
- German hospital tender restocking increased buying interest, absorbing available spot volumes despite steady retail demand.
- Elevated ocean freight and compliance costs added to conversion and logistics expenses, tightening supply economics.
Potassium Clavulanate Prices in North America
- In the USA, the Potassium Clavulanate Price Index rose by 5.48% quarter-over-quarter, from feedstock pressures.
- The average Potassium Clavulanate price for the quarter was approximately USD 64657.67/MT, CFR Los Angeles.
- Potassium Clavulanate Spot Price tightened as Price Index rose, reflecting higher freight and feedstock costs.
- Potassium Clavulanate Price Forecast points to moderate further gains as restocking intersects constrained spot availability.
- Potassium Clavulanate Production Cost Trend rose on Caustic Potash and refrigerated freight, pressuring conversion costs.
- Potassium Clavulanate Demand Outlook remains firm as prescription volumes steady and substitute shortages divert orders.
- Potassium Clavulanate Price Index reflected exporter discipline, thin port stocks, and longer reefer lead times.
- Exporters prioritized regional sales, limiting spot allocations and supporting firmer CFR offers into Los Angeles.
Why did the price of Potassium Clavulanate change in March 2026 in North America?
- Upstream Caustic Potash inflation sharply increased Chinese conversion costs, passing through to U.S. landed prices.
- Shanghai to Houston reefer freight rises, slot tightness lengthened lead times, adding inventory carrying costs.
- Steady prescription demand absorbed higher landed costs without provoking aggressive procurement or volume pull-forward.
For the Quarter Ending December 2025
North America
• In the USA, the Potassium Clavulanate Price Index fell by 0.41% quarter-over-quarter; freight reductions outweighed tariffs.
• The average Potassium Clavulanate price for the quarter was USD 85095.67/MT, reflecting landed-costs.
• Potassium Clavulanate Spot Price softened as China shipments and lower China-US freight eroded landed costs.
• Potassium Clavulanate Price Forecast anticipates modest gains early in the year as manufacturers replenish inventories.
• Potassium Clavulanate Production Cost Trend remained pressured by elevated caustic potash feedstock and compliance overheads.
• Potassium Clavulanate Demand Outlook is steady, driven by antibiotic shortages and formulators maintaining procurement and stockpiles.
• Inventories and export demand influenced the Potassium Clavulanate Price Index, tempering upside despite Indian controls.
• Chinese plant uptime sustained exports, Indian licences constrained volumes, moderating offers, and equilibrium.
Why did the price of Potassium Clavulanate change in December 2025 in North America?
• Lower China-to-US freight rates reduced landed costs, directly easing CFR offers during December's month-end adjustments.
• Indian export licensing tightened supply, but abundant Chinese shipments prevented acute shortages, muting upward price pressure.
• Steady winter antibiotic demand and sufficient importer coverage limited spot buying intensity, allowing offers to edge lower.
APAC
• In China, the Potassium Clavulanate Price Index fell by 0.4% quarter-over-quarter, reflecting elevated feedstock costs.
• The average Potassium Clavulanate price for the quarter was approximately USD 61193.33/MT, slightly stabilizing offers.
• Potassium Clavulanate Spot Price eased as inventories rose, and buyers constrained by tender ceilings limited purchases.
• Potassium Clavulanate Price Forecast indicates recovery into early 2026, driven by restocking and seasonal prescriptions.
• Potassium Clavulanate Production Cost Trend remained pressured by caustic potash inflation despite stable electricity tariffs.
• Potassium Clavulanate Demand Outlook is cautious with tender ceilings, selective international orders, and domestic procurement.
• Elevated year-end output increased bonded warehouse stocks, pressuring the Potassium Clavulanate Price Index slightly lower.
• Producers maintained high fermentation utilization; inventories grew, keeping sellers competitive on FOB despite muted demand.
Why did the price of Potassium Clavulanate change in December 2025 in APAC?
• High year-end domestic output increased available tonnes, overpowering mild respiratory-season demand and leaving stocks elevated.
• Caustic potash costs remained stable, keeping production costs neutral while exporters built inventories at warehouses.
• National bulk tender price ceilings and restrained international enquiries capped procurement, preventing FOB pricing upside.
Europe
• In Germany, the Potassium Clavulanate Price Index fell by 0.42% quarter-over-quarter, reflecting muted buying pressures.
• The average Potassium Clavulanate price for the quarter was approximately USD 85087.00/MT, CIF Hamburg basis.
• Potassium Clavulanate Spot Price remained pressured by abundant imports and balanced northern port inventories overall.
• Potassium Clavulanate Price Forecast indicates modest recovery early next year as buyers replenish inventories cautiously.
• Potassium Clavulanate Production Cost Trend was neutral as caustic potash and fermentation feedstocks remained unchanged.
• Potassium Clavulanate Demand Outlook stayed steady with hospital tender timing and stewardship measures tempering offtake.
• Price Index movements reflected exporters protecting margins while German buyers delayed year-end orders, softening offers.
• Potassium Clavulanate Price Index stability benefited from streamlined Hamburg clearance and steady freight, maintaining supply.
Why did the price of Potassium Clavulanate change in December 2025 in Europe?
• Comfortable import volumes from China and India boosted port stocks, limiting sellers' leverage and price upside.
• Stable caustic potash and fermentation feedstock costs left conversion expenses subdued, constraining upward price momentum.
• Digitalized Hamburg clearance and calm freight lanes expedited arrivals while domestic demand remained seasonally restrained.
For the Quarter Ending September 2025
North America
• In USA, the Potassium Clavulanate Price Index fell by 10.27% quarter-over-quarter, reflecting global oversupply and destocking.
• The average Potassium Clavulanate price for the quarter was approximately USD 85450.00/MT, CFR Los Angeles.
• Potassium Clavulanate Spot Price weakened as Asian exporters discounted amid export volumes and muted demand.
• Potassium Clavulanate Price Forecast anticipates near-term softness before stabilization as inventories gradually normalize and restocking.
• Potassium Clavulanate Production Cost Trend shows upward pressure from drayage increases on landed CFR basis.
• Demand Outlook stays muted as pharmaceutical buyers draw down stocks and further delay spot purchases.
• Elevated inventories pressured the Price Index, while logistics improvements allowed limited recovery broadly in offers.
• Chinese export competitiveness continued pressuring offers, though temporary plant turnarounds tightened supply to US markets.
Why did the price of Potassium Clavulanate change in September 2025 in North America?
• China and India export surges created inventory gluts, prompting aggressive discounting into United States markets.
• US manufacturers pre-stocked earlier, reducing fresh procurement and thereby diminishing immediate spot market demand significantly.
• Tariff uncertainty and logistics volatility delayed orders, suppressing spot activity despite occasional freight-driven cost increases.
APAC
• In China, the Potassium Clavulanate Price Index fell by 10.2384% quarter-over-quarter, driven by oversupply and destocking.
• The average Potassium Clavulanate price for the quarter was approximately USD 85333.33/MT FOB Shanghai sales.
• Potassium Clavulanate Spot Price showed short-term spikes amid logistical disruptions and temporary production maintenance constraints.
• Potassium Clavulanate Price Forecast indicates modest fluctuations with limited upside while inventories remain elevated regionally.
• Potassium Clavulanate Production Cost Trend reflected lower raw material prices, compressing producer margins and limiting cuts.
• Potassium Clavulanate Demand Outlook remains subdued due to weak pharmaceutical procurement and export restrictions reducing demand.
• Potassium Clavulanate Price Index weakness reflected aggressive domestic competition, maintenance-induced supply swings, and destocking-driven discounting.
• Inventory accumulation and tapered export flows pressured margins, while selective restocking could stabilise regional price trajectories.
Why did the price of Potassium Clavulanate change in September 2025 in APAC?
• Supply overshang from aggressive destocking and resumed output created downward pressure despite some maintenance-related shortages.
• Logistics disruptions and port congestion temporarily tightened availability, causing upward moves in FOB supply corridors.
• Weaker domestic procurement and soaring inventories combined with export barriers suppressed demand, prolonging price weakness.
Europe
• In Germany, the Potassium Clavulanate Price Index fell by 10.22% quarter-over-quarter in Q3 2025, reflecting abundant inventories.
• The average Potassium Clavulanate price for the quarter was approximately USD 85443.33/MT based on reported CFR Hamburg transactions.
• Potassium Clavulanate Spot Price softened as distributors aggressively cleared stock amid muted domestic procurement and euro appreciation.
• Potassium Clavulanate Price Forecast indicates modest downward pressure through year end as imports remain elevated from China.
• Potassium Clavulanate Production Cost Trend eased with lower energy and feedstock inputs, supporting competitive exporter pricing.
• Potassium Clavulanate Demand Outlook remains steady from pharmaceutical formulators, hospitals and outpatient units supporting baseline consumption.
• Potassium Clavulanate Price Index volatility increased owing to periodic shipping delays, port congestion, and intermittent demurrage fees.
• Inventory gluts and cautious procurement strategies pressured German domestic prices despite steady sectoral off-take and strategic replenishment.
Why did the price of Potassium Clavulanate change in September 2025 in Europe?
• Abundant inventories among German distributors reduced transactional urgency and depressed spot prices across the quarter ending September.
• Elevated import volumes from China combined with euro appreciation amplified downward pressure on local Potassium Clavulanate pricing.
• Shipping disruptions and port congestion intermittently tightened supply margins but overall muted demand sustained the bearish price trend.
For the Quarter Ending June 2025
North America
• The overall quarterly trend for Potassium Clavulanate spot prices in North America during Q2 2025 was downward, with average quarter-over-quarter price declines of approximately -11% from April through June. Prices fell from around USD 100,350 in April to USD 90,170 in June, continuing their descent into July, where prices further dropped to USD 85,165, reflecting sustained bearish momentum in the spot market.
• In June 2025, the U.S. market experienced sharp price declines driven primarily by global oversupply conditions. Chinese and Indian producers had ramped up production anticipating higher demand, but weaker-than-expected consumption led to inventory surpluses. Aggressive discounting by exporters, high pre-stocking earlier in the year by key buyers, and cautious spot purchasing due to tariff uncertainty intensified downward pressure on prices.
• Potassium Clavulanate Production cost trends in the quarter indicated some relief due to lower energy costs and easing inflation; however, supply plentifulness from Asia and efficient logistics maintained an oversupplied market, negating cost advantages for producers.
• Potassium Clavulanate Demand outlook for Q2 showed persistent weakness, particularly in pharmaceuticals and personal care sectors. Inventories accumulated from earlier overstocking cycles suppressed fresh demand, while downstream buyers adopted conservative procurement strategies amid trade policy uncertainties.
• The tariff environment introduced complexity, as reciprocal U.S. tariffs in April triggered import-export delays and cautious purchasing, indirectly contributing to price softness.
• Potassium Clavulanate Supply chains benefited from improved port operations and logistics efficiency, facilitating faster inventory clearance but also contributing to downward price pressure by easing product flows.
• Elevated inventory levels combined with subdued end-use demand reinforced a buyer’s market, limiting scope for price recovery in the short term.
• The U.S. macroeconomic context, including easing inflation reflected by a 0.5% monthly drop in the Producer Price Index in April, contributed to downward pricing sentiment.
• Looking into July 2025, Potassium Clavulanate spot prices continued to drop, influenced chiefly by ongoing global oversupply and pre-existing stock accumulation suppressing new procurement.
• Potassium Clavulanate Price forecast for the next quarter suggests continued downward or stabilized pricing unless a significant recovery in pharmaceutical demand or reduction in Asian supply emerges; input cost trends remain neutral but unlikely to shift dynamics substantially.
Asia-Pacific (APAC)
• APAC’s Potassium Clavulanate spot prices also exhibited a clear downward trajectory during Q2 2025, with average quarter-over-quarter losses near -11%, moving from approximately USD 100,200 in April to USD 90,000 by June.
• In June 2025, Chinese producers faced intense pricing pressure due to oversupply, shrinking producer price index (-3.6% YoY), and aggressive competition fueled by smaller producers ramping capacity during maintenance shutdowns at larger plants, leading to heightened inventory clearance efforts.
• Potassium Clavulanate Production cost trends were influenced by macroeconomic softness, including a slight deflationary pressure (consumer price index down 0.1% YoY) and industrial contraction signaled by PMI below 50; this weakened cost base was unable to offset price competition.
• Potassium Clavulanate Demand outlook remained subdued amid weakening domestic consumption and logistical challenges, including higher freight costs and trade tensions with the U.S., which constrained export opportunities and reduced procurement appetite downstream.
• The weakening of the Chinese Yuan against major currencies, though limited in Q2, affected export competitiveness marginally, compounded by persistent tariff and trade disputes.
• Surplus inventories grew as export demand faltered and domestic production outpaced consumption; producers resorted to significant discounts to move stock, resulting in continued price falls.
• Key downstream sectors, especially pharmaceutical formulation and manufacturing, showed cautious procurement behavior, refraining from aggressive restocking and awaiting market stabilization.
• Although maintenance outages at large production units briefly shifted production to smaller firms, this dynamic intensified price competition rather than supporting higher pricing.
• Potassium Clavulanate Price movement into July 2025 continued the declining trend, driven by persistent oversupply and weak seasonal demand for antibiotics, which is typical for warmer months.
• Potassium Clavulanate Price forecast for the next quarter anticipates stable to slightly bearish trends unless export conditions improve significantly or there are supply chain constraints that tighten availability; however, demand recovery in the pharmaceutical sectors remains a prerequisite.
Europe
• In Europe, Potassium Clavulanate spot prices mirrored global trends with sustained downward movement in Q2 2025, recording roughly an average 11% quarter-over-quarter price drop, with prices decreasing from about USD 100,295 in April to USD 90,110 in June and continuing down to USD 85,115 by July.
• June 2025 prices declined primarily due to elevated inventory levels caused by U.S. tariff-induced shipment diversions redirected toward Europe, combined with cautious buying as downstream buyers delayed new orders amid ample stocks and uncertain delivery schedules.
• Potassium Clavulanate Production cost trends reflected macroeconomic softness with stable but low inflationary pressures (Germany CPI rose 2.0% YoY in June), lower energy costs, and a modestly expanding manufacturing sector (PMI near 50.4), which minimized upward cost pressures on producers.
• Potassium Clavulanate Demand outlook in Q2 was characterized by inventory-driven buying rather than consumption growth, with pharmaceutical sectors maintaining steady but unspectacular demand aligned with ongoing clinical needs for antibiotic formulations including potassium clavulanate combinations.
• Logistics bottlenecks—port congestion, strikes, rail disruptions—affected supply chain efficiency but did not significantly elevate freight costs; these disruptions encouraged buyers to front-load or postpone orders, contributing to inventory accumulation.
• The appreciated Euro, gaining over 3% against the USD in June, made imports cheaper and exerted additional downward pressure on local prices, as distributors leveraged currency movements to maintain margins.
• Trade flow shifts from diverted U.S. shipments and sustained import volumes from Asia created supply surpluses within European distribution channels.
• Potassium Clavulanate Market sentiment reflected cautious replenishment with buyers awaiting clearer signals of demand recovery or stabilization, prolonging the bearish pricing environment.
• July 2025 prices remained pressured due to the combined impact of high inventories, subdued procurement activity, and stable supply conditions without major shocks to rebalance the market.
• Potassium Clavulanate Price forecast for the next quarter anticipates a continuation of the current trend or mild weakness unless supply chain constraints resolve and end-user demand strengthens, supported by steady hospital and pharmaceutical sector needs tied to antimicrobial treatments.
